CAMBRIDGE, Mass., August 17, 2026
Amylyx Pharmaceuticals, Inc. announced that it will report topline results from the Phase 3 LUCIDITY clinical trial of avexitide in patients with post-bariatric hypoglycemia (PBH) on August 18, 2026. The company said its senior management team will host a conference call and audio webcast at 8:00 a.m. ET following the release of the clinical data. The upcoming announcement represents an important clinical milestone for Amylyx as the company evaluates avexitide in a condition associated with episodes of abnormally low blood glucose following bariatric surgery. The LUCIDITY Phase 3 readout is the central focus of the company’s August 18 update, with the topline findings expected to provide new clinical evidence on the investigational therapy’s potential in PBH. The company has positioned avexitide among its investigational programs targeting diseases with significant unmet medical needs, making the upcoming data release an important development for its clinical pipeline.
Phase 3 LUCIDITY Trial Reaches Key Data Milestone
Amylyx Pharmaceuticals is advancing avexitide through the Phase 3 LUCIDITY clinical trial, with the upcoming topline announcement marking the next major step in the program’s development. The company has not disclosed the topline findings in the August 17 announcement, meaning the clinical efficacy and safety outcomes remain pending until the scheduled results presentation. The LUCIDITY readout will be closely watched because Phase 3 data can provide critical evidence needed to determine whether an investigational therapy can advance toward potential regulatory development. For the company, the timing of the announcement also provides an opportunity to communicate the results directly to investors, healthcare professionals and other stakeholders through its planned conference call and webcast. Rather than announcing preliminary conclusions ahead of the data release, Amylyx has confirmed that the full topline results will be communicated on August 18, keeping the immediate focus on the clinical evidence generated in the Phase 3 study.
Avexitide Targets Post-Bariatric Hypoglycemia
Avexitide is being investigated for post-bariatric hypoglycemia, a condition that can occur after bariatric surgery and is characterized by episodes of low blood glucose. The development program is therefore focused on addressing an area where patients may require additional therapeutic options. The LUCIDITY Phase 3 study is particularly important because its topline results will help clarify the clinical profile of avexitide in this patient population. The August 17 announcement itself does not provide efficacy measurements, statistical outcomes or safety findings from the trial, so those details should not be inferred before the official data release. This distinction is important for interpreting the announcement accurately: Amylyx has announced the timing of the Phase 3 results rather than announcing a positive or negative clinical outcome. The forthcoming data will therefore be the key source for determining whether avexitide demonstrated meaningful clinical benefit and whether the program can progress toward subsequent regulatory and development milestones.
Advertisement
Company Plans Results Conference Call and Webcast
Amylyx Pharmaceuticals will host its Phase 3 LUCIDITY results conference call and audio webcast at 8:00 a.m. ET on August 18, 2026. The company stated that participants can access the conference call using the designated U.S., Canada and international telephone numbers, while the live webcast will be available through the Investor section of the company’s website under Events and Presentations. The webcast is also expected to be archived for replay for 90 days following the event. The investor presentation will provide the company’s opportunity to discuss the topline LUCIDITY findings and their implications for avexitide development. Until those results are released, the key confirmed information is that the company has reached the point of reporting Phase 3 topline data. The announcement therefore represents a significant pipeline update for Amylyx, with the upcoming clinical readout expected to determine the next stage of development for avexitide in post-bariatric hypoglycemia.
Source: Amylyx Pharmaceuticals press relese
